Methimazole Dosing for Graves' Disease
For adults with Graves' disease, initiate methimazole at 15 mg daily for mild hyperthyroidism, 30-40 mg daily for moderate disease, and 60 mg daily for severe hyperthyroidism, with maintenance doses of 5-15 mg daily 1.
Adult Dosing
The FDA-approved dosing regimen divides the total daily dose into 3 administrations at 8-hour intervals 1. However, methimazole's pharmacokinetics allow for once-daily dosing, which is a key advantage over propylthiouracil 2.
Initial Treatment Strategy
- Mild hyperthyroidism: 15 mg/day
- Moderate hyperthyroidism: 30-40 mg/day
- Severe hyperthyroidism: 60 mg/day
- Maintenance: 5-15 mg/day 1
The 2018 French guidelines suggest starting at 5-10 mg daily for thiamazole (methimazole), with doses adapted to hyperthyroidism severity 3. Research supports that methimazole 30 mg/day normalizes free T4 more effectively than 15 mg/day in severe cases (free T4 ≥7 ng/dL), though adverse effects increase with higher doses 4.
Treatment Duration
Standard treatment courses last 12-18 months 2, 5. However, compelling evidence shows that extended treatment for 60-120 months with low-dose methimazole achieves remission rates of 85% versus 47% with conventional 18-24 month courses, with no additional adverse effects observed during prolonged therapy 6.
Pediatric Dosing
For children, initiate methimazole at 0.4 mg/kg/day divided into 3 doses at 8-hour intervals, with maintenance at approximately half the initial dose 1.
Important Pediatric Considerations
- Methimazole is the preferred antithyroid drug for pediatric patients due to severe hepatotoxicity risks with propylthiouracil 1
- Treatment duration should be 24-36 months in children 5
- Doses <0.7 mg/kg/day are as effective as higher doses for normalizing free T4 in mild-to-moderate disease, with significantly lower adverse event rates 7, 8
- The incidence of neutropenia and liver dysfunction increases substantially at doses >0.7 mg/kg/day (21.4% neutropenia vs 0% at <0.4 mg/kg/day) 7
Pregnancy Dosing
During pregnancy, use propylthiouracil in the first trimester, then switch to methimazole at 5-10 mg daily for the second and third trimesters 3.
Pregnancy-Specific Algorithm
First trimester (weeks 0-13): Use propylthiouracil 50-150 mg daily to avoid methimazole-associated congenital malformations 3
Second and third trimesters: Switch to methimazole 5-10 mg daily to avoid propylthiouracil hepatotoxicity 3
Monitoring during switch: Increase thyroid function monitoring to every 2 weeks when switching medications, as this transition can destabilize thyroid balance 3
Treatment goal: Maintain maternal free T4 at or just above the upper limit of normal (non-pregnant reference range) 3
Consider discontinuation: If hyperthyroidism improves significantly during pregnancy (common as pregnancy progresses), attempt to reduce or discontinue antithyroid drugs, particularly between weeks 6-10 or in later trimesters 3
Critical Pregnancy Warnings
- Use only adapted-dose monotherapy—if combination therapy with levothyroxine was used pre-pregnancy, stop levothyroxine immediately and continue only methimazole at adjusted doses 3
- Monitor thyroid function every 2-4 weeks throughout pregnancy 3
- Radioactive iodine is absolutely contraindicated 3
Key Safety Considerations
Adverse Effects Requiring Monitoring
- Agranulocytosis and neutropenia: More common with higher doses; monitor complete blood counts
- Hepatotoxicity: Occurs in 14-28% of patients (usually mild), primarily in first 2 months 2
- Vasculitis: Rare but severe; instruct patients to report new rash, hematuria, decreased urine output, dyspnea, or hemoptysis 1
- Skin reactions: Occur in 5-10% of patients 2
Drug Interactions
- Warfarin: Methimazole may increase anticoagulant effect; monitor PT/INR closely 1
- Beta-blockers, digoxin, theophylline: Doses may need reduction as patient becomes euthyroid 1